| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
This compound is classified as an amino acid derivative targeting leucine-related metabolic pathways and serves as a structural mimic of the branched-chain amino acid leucine, potentially interacting with enzymes involved in protein synthesis, mTOR signaling, and branched-chain amino acid metabolism.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
Amino acids and amino acid derivatives such as this compound influence the secretion of anabolic hormones, supply of fuel during exercise, mental performance during stress, and prevention of exercise-induced muscle damage. They are recognized as beneficial ergogenic dietary substances in commercial formulations. |
| ln Vivo |
In vivo studies on analogous leucine derivatives demonstrate effects on nitrogen retention, muscle protein synthesis, and recovery from physical exertion. These compounds support metabolic homeostasis and may modulate signaling pathways such as mTORC1, which regulates cell growth and metabolism in response to amino acid availability.
|
| Enzyme Assay |
Cell-free binding assays for leucine derivatives typically involve radioligand displacement studies using purified leucine-binding proteins or enzymes, such as leucine aminopeptidase or branched-chain amino acid transaminase. Binding affinity is measured by competitive displacement of labeled substrate followed by scintillation counting or fluorescence polarization.
|
| Cell Assay |
Cell-based assays for leucine derivatives commonly use primary hepatocytes or myotube cultures to assess effects on mTOR pathway activation. Cells are serum-starved then treated with the compound for 30-60 minutes, followed by Western blot analysis of phosphorylated S6K1, 4E-BP1, or AKT using specific antibodies.
|
| Animal Protocol |
Animal studies with leucine derivatives are typically conducted in rodent models (rats or mice). Animals receive oral or intraperitoneal administration at doses ranging from 50 to 500 mg/kg body weight. Assessments include muscle protein synthesis rates via stable isotope tracer incorporation, nitrogen balance studies, and exercise performance in treadmill or swimming protocols.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of leucine derivatives generally include moderate oral bioavailability (20-60%), peak plasma concentration reaching 1-4 hours post-dose, plasma half-life of 2-5 hours, volume of distribution consistent with total body water (0.5-1.0 L/kg), and elimination primarily via urine as metabolites or unchanged drug.
|
| Toxicity/Toxicokinetics |
Toxicological profiles of leucine derivatives typically show low acute oral toxicity with LD50 > 2000 mg/kg in rodents. Repeat-dose studies up to 28 days at therapeutic doses reveal no significant organ toxicity, minimal effects on body weight or food consumption, and no mutagenicity in Ames test or chromosomal aberration assays.
|
| References | |
| Additional Infomation |
This compound exists as a white to off-white solid powder with molecular formula C8H18FNO6S and molecular weight 275.30, soluble in DMSO (100 mg/mL). It is recommended for research use only, not for human therapeutic applications, and should be stored at 4degC under nitrogen protection, protected from moisture.
|
| Molecular Formula |
C8H18FNO6S
|
|---|---|
| Molecular Weight |
275.30
|
| Exact Mass |
275.084
|
| CAS # |
848949-85-9
|
| PubChem CID |
11448742
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.143
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
17
|
| Complexity |
240
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
S(O)(O)(=O)=O.[C@H](N)(CC(F)(C)C)C(=O)OCC
|
| InChi Key |
VWRTUFGLEMCOLL-RGMNGODLSA-N
|
| InChi Code |
InChI=1S/C8H16FNO2.H2O4S/c1-4-12-7(11)6(10)5-8(2,3)9;1-5(2,3)4/h6H,4-5,10H2,1-3H3;(H2,1,2,3,4)/t6-;/m0./s1
|
| Chemical Name |
ethyl (2S)-2-amino-4-fluoro-4-methylpentanoate;sulfuric acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (363.24 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6324 mL | 18.1620 mL | 36.3240 mL | |
| 5 mM | 0.7265 mL | 3.6324 mL | 7.2648 mL | |
| 10 mM | 0.3632 mL | 1.8162 mL | 3.6324 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
